Home » Blog » Lyrica pregabalin: Side effects, dosage, uses, and more
Regarding long-term safety data for the chronic use of pregabalin and gabapentin, in the case of pregabalin for the treatment of anxiety disorders, good tolerability has been observed with effective disease management (12). Both responders and non-responders showed low and similar discontinuation rates, with a good safety profile across a dosage range of 150–600 mg (12). Another study examined the effects of pregabalin over 2 years with doses above 300 mg for the treatment of patients with partial-onset epilepsy and found a higher discontinuation rate but good disease control (13). The most common but transient adverse events were dizziness, somnolence, headaches, and asthenia (13). In patients with chronic epilepsy treated for more than 3 years with 1,800 mg of gabapentin, 39% discontinued gabapentin owing to lack of efficacy (15). This meta-analysis did not find significant differences in overall complications, possibly due to the use of low doses of the drugs in most studies.
McNemar or Wilcoxon sign-rank tests were used to determine the statistical significance of within-group changes between the pre-index and follow-up periods. All analyses were performed using the SAS software system, PC version 9.2 (SAS Institute, Inc., Cary, NC, USA). The study protocol was approved by the Scientific Review Committee, which has been approved by the NHS South-East Multicenter Research Ethics Committee. For non-randomized studies, the risk of bias was assessed using the Methodological Index for Non-Randomized Studies (MINORS) with a total of 12 items (25). For non-comparative studies, scores ranging from 0 to 4, 5 to 7, 8 to 12, and ≥13 were categorized as very low, low, fair, and high quality, respectively. In comparative studies, scores ranging from 0 to 6, 7 to 10, 11 to 15, and ≥16 were categorized as very low, low, fair, and high quality, respectively (25).
Explore Mayo Clinic studies testing new treatments, interventions and tests as generic lyrica cost a means to prevent, detect, treat or manage this condition. The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was financially supported by Viatris, which funded the statistical analysis and the medical writing services. No financial compensation was provided to the physicians for their contributions as authors of this publication. Forest plot illustrating the change in SF-12/SF-36/EQ-5D, which was significantly greater in the pregabalin group than in the gabapentin group. Doctronic is not a doctor, does not provide medical advice, does not practice medicine, and does not provide patient care.